Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC
Category: #health  | By Nikita Chaurasia  | Date: 2020-03-30 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC

Esperion Therapeutics, a US-based public pharmaceutical company, reportedly unveiled that two pooled data analyses from its 4 Phase 3 clinical studies of NEXLETOL and outcomes from Phase 2 trial of NEXLIZET were showcased during the ACC.20/WCC.

In a poster session that was showcased by Harold E Bays, FOMA, MD, FTOS, FACE, FTOS, FNLA, FACC., it was highlighted that in Phase 2 trial, NEXLIZET lowered LDL-C significantly by a 40% mean as compared placebo, lowered hsCRP by 25% in comparison to the baseline, and further did not worsen glycemic control.

Along with the first poster, an additional poster session was conducted by Eric S. G. Stroes, MD., PhD. This poster signified that inside the pooled Phase 3 trials, NEXLETOL substantially decreased hsCRP in patients suffering from hypercholesterolemia irrespective of the intensity or presence of background statin treatment.

The third and final poster session was conducted by Maciej Banach, Ph.D., FESC, FAHA, MD. In the session it was highlighted that in Phase 3, NEXLETOL facilitated significant additional lowering of LDL-C while also significantly lowering other lipid endpoints, irrespective of background ezetimibe presence. Most notably, NEXLETOL’s safety profile was similar without or with background ezetimibe treatment.

Tim Mayleben, President and the Chief Executive Officer of Esperion stated that the company is thrilled with the final outcomes of Phase 2 trials that signifies NEXLIZET gained a 40 percent LDL-C lowering, a substantial 25 percent decrease in hsCRP and did not exacerbate glycemic control in patients suffering from Type 2 diabetes. The pooled analyses from Phase 3 LDL-C decreasing development program shows that NEXLETOL can be safely integrated with multiple LDL-C medicines, crucial to aid more patients to achieve their LDL-C objectives.

Mayleben further added that these analyses assure the safety and efficacy of the company’s medicines for millions of patients wanting to decrease their bad cholesterol levels.

 

Source credit: https://www.esperion.com/investors-media/press-releases/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Shell trades off Russian retail business to native oil producer Lukoil

Shell trades off Russian retail business to native oil producer Lukoil

By Nikita Chaurasia

Energy giant Shell plans on selling more than 400 petrol stations of its Russian subsidiary Shell Neft to Lukoil, the second largest oil producer in the country after state backed Rosneft. As several Western oil and gas firms seek to get rid of th...

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

By Nikita Chaurasia

Mitsubishi Electric Europe and Siemens Mobility have recently signed a memorandum of understanding (MoU) to work together in silicon carbide (SiC) traction power technology. As per reports, JR Central’s next-generation N700S Shinkansen train...

Legato opens 80 new jobs in its Limerick Research & Development hub

Legato opens 80 new jobs in its Limerick Research & Development hub

By Nikita Chaurasia

The global capability center of a leading U.S. health care insurance company, Legato Health Technologies is planning to build an additional 80 posts at its Limerick facility. It would bring the total number of staff to 200, which the fir...